Castle Biosciences (CSTL) closed at $34.50 on November 12, 2026, up 1.5% from the previous close, on volume of 406,240 shares (30-day average 384,386).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Strangle or Risk Reversal | 20-Nov-2630 P : 40 C | 1,500 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
PRNewswire (Thu, 12-Nov 7:00 AM ET)
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
PRNewswire (Wed, 11-Nov 4:30 PM ET)
PRNewswire (Wed, 11-Nov 7:00 AM ET)
Guggenheim Remains a Buy on Castle Biosciences (CSTL)
TipRanks (Tue, 10-Nov 7:27 AM ET)
Castle Biosciences Reports Third Quarter 2026 Results
PRNewswire (Thu, 5-Nov 4:05 PM ET)
Castle Biosciences to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 28-Oct 7:01 AM ET)
PRNewswire (Thu, 15-Oct 7:00 AM ET)
PRNewswire (Mon, 12-Oct 4:31 PM ET)
PRNewswire (Wed, 30-Sep 4:30 PM ET)
PRNewswire (Mon, 28-Sep 7:00 AM ET)
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Castle Biosciences trades on the NASDAQ stock market under the symbol CSTL.
As of November 13, 2026, CSTL stock price declined to $32.80 with 45,690 million shares trading.
CSTL has a beta of 0.04, meaning it tends to be less sensitive to market movements. CSTL has a correlation of 0.00 to the broad based SPY ETF.
CSTL has a market cap of $1.00 billion. This is considered a Small Cap stock.
Last quarter Castle Biosciences reported $103 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.22.
In the last 3 years, CSTL traded as high as $44.28 and as low as $14.59.
The top ETF exchange traded funds that CSTL belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
CSTL has underperformed the market in the last year with a price return of -5.8% while the SPY ETF gained +11.0%. However, in the short term, CSTL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.4% vs -2.6% return in SPY. But in the last 2 weeks, CSTL shares have been beat by the market, returning -14.8% compared to an SPY return of -2.4%.
CSTL support price is $33.29 and resistance is $35.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CSTL shares will trade within this expected range on the day.
